Browse by Medical Category
Accepting New Patients
Michael A. Fifer, MD, directs the Cardiac Cath Lab, Interventional Cardiology Associates, and the Hypertrophic Cardiomyopathy Program at the Massachusetts General Hospital Heart Center.
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
View my most recent publications at PubMed
Rothman RD, Baggish AL, O?Callaghan C, Lowry PA, Bhatt AB, MacRae CA, Yannekis G, Sanborn DM, Mela T, Yeh RW, Palacios I, Vlahakes GJ, Fifer MA. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. Am J Card 2012;110:1169-74.
Elmariah S, Fifer MA. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Curr Treat Options Cardiovasc Med 2012;14:665-678.
Sanborn DMY, Sigwart U, Fifer MA. Patient selection for alcohol septal ablation for hypertrophic obstructive cardiomyopathy: clinical and echocardiographic evaluation. Interv Cardiol 2012;4:349-59.
Shimada YJ,. Passeri JJ, Baggish AL, O?Callaghan C, Lowry PA, Yannekis G, Abbara S, Ghoshhajra BB, Ho CY, Januzzi JL, Seidman CE, Fifer MA. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiology HF 2013;1:480-7.
MGH Hotline 6.10.11 U.S. Rep. Erik Paulsen, co-chair of the Medical Technology Caucus, visited the MGH on May 18 to tour the Tissue Engineering and Organ Fabrication Laboratory in the Richard B. Simches Research Center and the Cardiac Catheterization Laboratory on Blake 9.
Study of 'planned' heart attacks identifies markers that could improve treatment, save lives.
Back to Top